This comprehensive review revealed that old age is a real risk factor for IgAN progression to ESRD. The incidence of ESRD in the older IgAN patients was 1.95 times higher than that in the non-older IgAN patients. Moreover, the risk of IgAN progression to ESRD of the older patients in Asia was higher than that of the older patients in Europe.
Introduction
IgA nephropathy (IgAN) was first reported by Berger and Hinglais in France in 1968 [1] . Today, IgAN has become the most common primary glomerulonephritis worldwide [2] , especially in Southeast Asia. Approximately 30-40% of IgAN patients progress to end-stage renal disease (ESRD) within 20 years [3] . In Italy, and Europe as a whole, approximately 24% of histologically examined patients have IgAN as the cause of ESRD [4] . In the assessment of most of the IgAN clinical trials, we previously concluded that IgAN was the most common cause of ESRD in China [5] . IgAN generally affects young people <30 years of age. In the literature from the 1990s, patients older than 50 years accounted for only 2.3% of all the patients [6] , but this proportion has risen to 18.3% recently [7] . This change may be caused by an increased human life expectancy, increasing the proportion of elderly patients.
The world is likely to have one billion people older than 65 years by 2030, accounting for 13% of the total population [8] . With life expectancy increasing and medical conditions progressing, the age of the population in developed countries is accelerating [9] [10] [11] . We found few reports of the impact of aging on IgAN [6, 7, 12, 13] , and the existing studies did not reveal the impact of aging on longterm kidney survival in IgAN patients. Some studies found that aging would increase the risk of IgAN progressing to ESRD [7, 12] . However, other studies showed that aging was a protective factor against developing ESRD [6] . To clarify the impact of aging on IgAN progression to ESRD, we conducted the following meta-analysis.
Methods

Search Strategy
We used the following terms for standard medical subject headings and free-text words: IgA glomerulonephritis, IgA nephropathy, Berger disease, immunoglobulin A nephropathy, prognosis, long-term, outcome, and predict. We only made slight modifications to the basic search template to optimize the search strategy in the individual electronic databases. We also reviewed the references cited in all of the studies selected for review. The investigators who had published any study on the relationship between aging and IgAN were also contacted.
From April 1, 2012 , to June 1, 2012, we screened eight electronic databases: PubMed/MEDLINE, EMBASE, Science Citation Index, OVID evidence-based medicine, Chinese Biomedical Literature and Chinese science and technology periodicals (CNKI, VIP, and Wan Fang). All of the relevant studies were published from January 1980 to May 2012. Two searchers conducted the search independently. If one of the searchers thought that the article was appropriate, the study was selected. The search was repeated in September 2012, using PubMed/MEDLINE to capture any articles that were published after the original search date.
Study Selection
The inclusion criteria were case-control, cohort studies published in any language. Cross-sectional studies were excluded because they cannot clearly identify the causal relationship between observed indicators and diseases. The included studies needed to have an older group. IgAN was proven by biopsy. We excluded patients with secondary IgAN. The end point was progression to ESRD, chronic kidney disease stage 5, CRF or the need for renal replacement therapy, and the follow-up period was longer than 12 months. The exclusion criteria were the following: not having an older group (older than 50 years of age), no matched outcomes, lack of raw data and data duplication.
Quality Assessment
We used the US preventive task force methodology to critically assess the quality of the studies included in this review [14] .
The evaluation criteria for the cohort studies were the following: (1) initial assembly of the cohort; (2) maintenance of comparable groups; (3) attrition; (4) clear definitions of exposure; (5) assessment of measurements; (6) adjustment for important potential confounders, and (7) inclusion of all important results [15] . Instead of scores, we used 'good', 'fair', and 'fail' to judge the overall quality of the included studies. When both reviewers judged a study to be 'fair', the study was evaluated in the final round. If the results of the two reviewers were significantly different, i.e. one judged a study as 'good' and another as 'fail', the committee conducted a collective discussion to arrive at a final opinion.
Data Extraction and Statistical Analysis
Data on trial design, sample size, nationality, males, age, exposure definition, outcome definition, follow-up time, renal function, hypertension, events were extracted. Relative risk (RR) and 95% confidence intervals were used to analyze the dichotomous data. The random effects model was weighted using the DerSimonian and Laird methods [16] . A random effects model was chosen a priori because of the belief that variation in the study populations and underlying diseases between the groups (older and younger groups) would result in inter-study heterogeneity beyond sampling variability. Heterogeneity between studies was tested using the χ 2 test. When the heterogeneity results showed a p < 0.10, heterogeneity was considered to be present. The size of heterogeneity in the included studies was assessed using I 2 [17] . All of the analyses were performed using Review Manager 5.1 (The Nordic Cochrane Centre, Rigshospitalet 2008). 
Results
Identification of Studies and Their Evaluation
Nine studies published before September 30, 2012, were identified as eligible for inclusion ( fig. 1 ) [7, 12, 13, 18, [20] [21] [22] [23] [24] . One cross-sectional study and 2 duplicated trials were excluded [19, 25, 26] . The main features of these studies are shown in table 1 . The quality assessment of the studies varied from two 'fair' to two 'good'. All 9 cohort studies documented the initial assembly of the cohort, attrition, clear definitions of exposure and assessment of measurements ( table 2 ) .
Study Characteristics
Nine studies, 4 of them from Japan, one from France, one from Iran, one from Italy, one from Spain, and one from China, containing a total of 6,543 patients (all of the included patients were older than 15), were selected Goto [7] yes yes yes yes yes yes no good/fair Kuhara [18] yes yes yes yes yes yes yes good/good Takeda [20] yes yes yes yes yes yes yes good/good Frimat [13] yes yes yes yes yes yes yes good/good Soleymanian [12] yes no yes yes yes no no fair/fair Yang [21] yes yes yes yes yes yes yes good/good Ferro [22] yes yes yes yes yes yes no good/good Rivera [23] yes yes yes yes yes yes yes good/good Yokoyama [24] yes yes yes yes yes yes yes good/good for the meta-analysis, and there were 6 studies that were conducted using an Asian population. One reason was that the incidence of IgAN in Asia was higher compared with other continents [27] . The longest mean followup time was 4.9 years, and the shortest was 23.5 months. Four studies were multi-center studies [7, 13, 23, 24] . The age limit for the older group in the 4 studies was 50 years old [12, 13, 18, 20] . Table 3 lists the basic clinical indicators measured in the included study populations.
Different Characteristics between the Groups in the Included Studies
Many studies showed that hypertension, hematuria, proteinuria, serum IgA level, baseline renal function and serum cholesterol level could impact the prognosis of IgAN [28, 29] . Therefore, we decided to conduct metaanalyses of other risk factors between the groups ( table 4 ). The incidence of hypertension in the older group was significantly higher than in the younger group. In the incidence data, proteinuria was significantly different between the groups [13, 24] . Moreover, other studies also found proteinuria was significantly different between the groups [18, 20, 21] . The incidence of an elevated serum IgA level was significantly different between the groups, with the older group having a higher level [13, 18, 20] . Moreover, we found that serum cholesterol levels between the groups were significantly different.
Because of the lack of information in the original studies, other factors, such as treatment, blood glucose level, pathological grade and uric acid, were not analyzed here. Takeda Three studies found baseline renal function of the older groups was generally worse than that of the younger groups [13, 21, 24] , but the time between disease onset and diagnosis in the older group and the younger group was not significantly different, which proves that aging itself can damage renal function in IgAN patients and adversely impact IgAN prognosis.
Based on the results above, the older and younger groups were significantly different in the incidence of hypertension, proteinuria, serum IgA level, serum cholesterol level and baseline renal function, but the incidence of gross hematuria was not significantly different.
Effect of Aging on IgAN Prognosis
Pooled analyses found that the incidence of ESRD in the older IgAN patients was 1.95 times higher than that in the non-older IgAN patients [RR random effects model 1.95 (1.27-3.01)]. The combined results showed heterogeneity (p = 0.007, I 2 = 62%; fig. 2 ). So, we used a fixed effects model instead of a random effects model, which did not change our initial result. Sensitivity analysis excluding each individual study at a time was similar in the direction and magnitude of the overall estimates. Additionally, the sources of heterogeneity were investigated using subgroup analysis. The age limit of the older group ranged from 50 to 65 years. In the subgroup analysis, we found that the RR of the '60-and 65-year-old group' was 1.80 (95% CI: 1.15-2.83; fig. 3 ). The RR of the '50-yearold group' subgroup was 2.06 (95% CI: 0.77-5.50), and did not have statistical significance ( fig. 3 ). In the hypertension, proteinuria, serum cholesterol level, baseline renal function and serum IgA level subgroup analyses, none of the RR of 'significant differences in hypertension (or proteinuria, serum cholesterol level, baseline renal function, serum IgA level) between older group and non-older group' subgroups had statistical significance. But the RR of the 'no mention or no significant differences' subgroups ranged from 1.70 to 2.27 ( fig. 4-8 ). This may indicate that the age limit and those traditional risk factors of IgAN were the sources of heterogeneity between studies. Controlling for those factors when comparing the groups may be good for exposing the true impact of aging on IgAN. In addition, we conducted a funnel plot analysis for the included studies ( fig. 9 ).
In the study location subgroup analysis, the RR (2.56) of the Asian countries was much higher than the RR (1.11) of the European countries. The p value for subgroup differences was 0.02 (p < 0.10; fig. 10 ).
Discussion
IgAN often occurs in young people, but there is still controversy whether aging could increase the risk of IgAN progressing to ESRD. To ascertain the true impact of aging on the incidence of IgAN patients developing ESRD, we conducted a systematic review and meta-analysis. We found that aging could significantly increase the incidence of IgAN patients developing ESRD, and traditional risk factors (hypertension, proteinuria, serum cholesterol, serum IgA level and baseline renal function) of IgAN did not change the results.
The older people had a higher incidence of underlying diseases and more severe symptoms of IgAN, and these 248 underlying diseases and symptoms were often the risk factors of IgAN. To confirm these confounding factors, we conducted a cross-sectional analysis. The results showed that there were significant differences between the groups for hypertension, proteinuria, serum IgA level, serum cholesterol level, baseline renal function, and the older group was generally worse than the younger group.
Then, we conducted a longitudinal meta-analysis. Pooled analyses of all of the studies found that the incidence of ESRD in the older IgAN patients was 1.95 times higher than in the non-older IgAN patients. The results showed heterogeneity. In the subgroup analyses, we found that the age limit and hypertension, proteinuria, serum IgA level, serum cholesterol level, baseline renal function may be the sources of heterogeneity between studies. In those subgroup analyses, the 'no mention or no significant difference' subgroups, due to the relative elimination of the impact of those factors, revealed the real role of aging itself (RR ranged from 1.70 to 2.27).
There were 4 studies that found a positive, significant correlation between aging and the incidence of ESRD among the IgAN patients. All of them were from Asian countries. And our subgroup analysis of the study location found that the RR (2.56) of the Asian countries was much higher than the RR (1.11) of the European countries. So, we could conclude that the risk of IgAN progression to ESRD of the older patients in Asia was higher than that of the older patients in Europe.
The reason may be due to genetic differences between races. It has been reported that, consistent with the higher prevalence of IgAN in Asians, the frequency of protective alleles was significantly lower in the Chinese cohort compared with the European group [30] . The frequency of the risk alleles was highest in East Asians, intermediate in Europeans and lowest in African-Americans [30, 31] . They also examined global geographic variation in the genetic risk for IgAN by applying the newly refined IgAN risk score in 6,319 healthy individuals across 85 worldwide populations. The result showed that the mean standardized risk score was lowest for Africans, intermediate for Middle Easterners and Europeans, and highest for East Asians and Native Americans [31] . The analysis of the United States Renal Data System dataset confirmed that the percentage of ESRD attributable to IgAN was 5-fold greater for Caucasian and 15-fold greater for Asian Americans compared to African-Americans [31] .
The major mechanism is the impact of aging itself, which includes functional and structural changes, such as a decline in renal blood flow, age-related nephrosclerosis, systemic and local renal inflammation, and diminished renal adaptive capacity. With increasing age, renal blood flow progressively decreases and renal vascular resistance increases [32] [33] [34] . Decreased renal blood flow, renal vascular resistance and narrowing in the arteries and arterioles all result in nephrosclerosis. Nephrosclerosis is known to occur with aging based on autopsy series [35] . The incidence of glomerular sclerosis was <5% in those under the age of 40; however, by age 80, the incidence increased to 30% [34, 36] . Our included studies [7, 21] clearly showed that the incidence of glomerulosclerosis in the older group was significantly higher than in the younger group. Three studies also confirmed that the incidence of tubulointerstitial fibrosis in the older group was significantly higher than in the younger group [18, 20, 21] . The same trend was seen for arteriolosclerosis [20, 21] . Glomerulosclerosis, tubular atrophy, interstitial inflammation and hyaline arteriolosclerosis correlated with progression in all IgAN patients and also in IgAN patients with a normal initial serum creatinine [37] . Physiological aging is associated with a chronic subclinical systemic inflammation state, termed inflammaging [38] . Interestingly, Frimat et al. [13] found that only endarteritis was significantly more common in the older patients. During inflammaging, inflammatory markers increase [39] , and inflammaging may be associated with accelerated age-related loss of renal function and IgAN progression [39, 40] . Meanwhile, with the nephrosclerosis incidence increasing and the reduction in renal autacoid modulatory capacity, particularly at the vasodilating prostaglandin level, in One of the advantages of this meta-analysis is an adequate follow-up time for the included studies, and the average follow-up time was greater than or almost 2 years (24 months). The first limitation is that we may not thoroughly separate the independent effects of covariates from aging without getting raw data. The second limitation is that there is heterogeneity. There was heterogeneity in the source populations, sample sizes and underlying diseases between the groups (older and younger groups). Specifically, the underlying diseases were quite different. However, the overall validity of our conclusion was supported by the highly significant association between aging and a high risk of IgAN progressing to ESRD. Seven of the nine correlation coefficients were positive in the direction of progressing to ESRD in the older groups. Both the random effects and fixed effects models confirmed the validity of the results. Sensitivity analysis excluding each indi- 251 vidual study at a time was similar in the direction and magnitude of the overall estimates. In summary, our meta-analysis found that old age is a real risk factor for IgAN progression to ESRD. Future studies need to examine the strength of the effect of aging leading the progression to ESRD in IgAN patients and control for other relevant factors to further clarify the impact of aging. Because a randomized trial is impossible, a cohort study design is best and will allow for the identification of incident cases, establishment of temporality, and the ability to make powerful, etiologic inferences. 
